Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review
- PMID: 36050418
- DOI: 10.1007/s00415-022-11356-9
Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review
Abstract
Background: The link between paraneoplastic neurological syndromes (PNS) and renal cell and bladder cancer (RCC/BC) is rare and uncertain. Our aim was to clinically evaluate, in light of the updated PNS criteria, these uncommon associations.
Methods: Retrospective nationwide cohort chart review study and systematic review of the literature.
Results: After excluding 5 patients due to the diagnosis of another co-occurrent malignancy, 10/18 patients with RCC and 8/18 patients with BC were identified. A total of 31 cases were previously published, yielding an overall series of 27/49 RCC and 22/49 BC patients. There was a predominance of cerebellar syndromes in both cancers (10/27, 37% for RCC; 9/22, 41% for BC), followed by encephalitis in 9/27 (33%) patients with RCC and encephalomyelitis/sensory neuronopathy in 5/22 (23%) patients with BC. The detection of high-risk Abs was more frequent among BC patients (16/19, 84% vs. 3/13, 23% in RCC, p = 0.0009), Ri antibodies being the most frequent thereof. After applying the updated PNS criteria, patients with BC met highest degrees (possible, probable, and definite) of certainty for PNS diagnosis (20/22, 91% vs. 16/27, 59% in RCC, p = 0.021).
Conclusion: A second neoplasm should always be ruled out before establishing the diagnosis of PNS in patients with RCC or BC. However, while this association remains dubious for most patients with RCC, a casual role is more probable in patients with BC and high-risk antibodies presenting with cerebellar ataxia, brainstem encephalitis or encephalomyelitis/sensory neuronopathy.
Keywords: Bladder cancer; Cerebellar ataxia; Neural antibodies; Paraneoplastic neurological syndromes; Renal cell cancer.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
References
-
- Graus F, Vogrig A, Muñiz-Castrillo S, Antoine J-CG, Desestret V, Dubey D, Giometto B, Irani SR, Joubert B, Leypoldt F, McKeon A, Prüss H, Psimaras D, Thomas L, Titulaer MJ, Vedeler CA, Verschuuren JJ, Dalmau J, Honnorat J (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 8:e1014. https://doi.org/10.1212/NXI.0000000000001014 - DOI
-
- Storstein A, Vedeler CA (2007) Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects. Advances in clinical chemistry. Elsevier, Amsterdam, pp 143–185
-
- Hébert J, Riche B, Vogrig A, Muñiz-Castrillo S, Joubert B, Picard G, Rogemond V, Psimaras D, Alentorn A, Berzero G, Desestret V, Rabilloud M, Honnorat J (2020) Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm 7:e883. https://doi.org/10.1212/NXI.0000000000000883 - DOI
-
- Storstein A, Raspotnig M, Vitaliani R, Giometto B, Graus F, Grisold W, Honnorat J, Vedeler CA (2016) Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes. J Neurol 263:1001–1007. https://doi.org/10.1007/s00415-016-8090-7 - DOI
-
- Global Cancer Observatory. https://gco.iarc.fr/ . Accessed 11 Oct 2021
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
